Albumin Baxalta: Uses, Dosage & Side Effects

What Is Albumin Baxalta and What Is It Used For?

Albumin Baxalta 50 g/l contains human albumin, a major protein that constitutes approximately 60% of the total protein content in blood plasma. Albumin is naturally produced by the liver and plays several critical physiological roles: it maintains oncotic (colloid osmotic) pressure that keeps fluid within the blood vessels, serves as a transport protein for hormones, enzymes, fatty acids, bilirubin, and numerous medications, and functions as a free radical scavenger providing antioxidant protection. The product is manufactured by Takeda Manufacturing Austria AG from human blood collected from carefully screened donors.

As a plasma substitute belonging to the pharmacological group of plasma protein fractions, Albumin Baxalta is specifically designed to replace the albumin that has been lost through bleeding, burns, surgical procedures, or various medical conditions that cause hypoalbuminemia (abnormally low levels of albumin in the blood). When administered intravenously, the albumin molecules draw water from the interstitial space into the bloodstream through their oncotic effect, thereby expanding the circulating blood volume and helping to maintain adequate organ perfusion and tissue oxygenation.

The product is available in glass vials containing either 250 ml or 500 ml of solution. Each 250 ml vial contains 12.5 grams of human albumin, while the 500 ml vial contains 25 grams. The solution is clear and slightly viscous, appearing nearly colorless to yellow, amber, or green in color. It is a sterile preparation intended exclusively for intravenous administration in healthcare facilities equipped to monitor patients receiving blood products.

Human albumin solutions, including Albumin Baxalta, are listed on the WHO Model List of Essential Medicines, reflecting their importance in global healthcare. They are among the most widely used plasma-derived medicinal products in intensive care units, surgical departments, and emergency medicine settings worldwide. The decision to use albumin rather than an artificial colloid solution, as well as the specific dose required, is made by the treating physician based on the patient's overall clinical condition, laboratory values, and hemodynamic parameters.

Clinical Indications

Albumin Baxalta is indicated for the restoration and maintenance of circulating blood volume in a variety of clinical scenarios where volume replacement is necessary and the use of a colloid solution is considered appropriate. The primary indications include:

• Hypovolemia: Acute blood volume loss due to hemorrhage, trauma, surgery, or burns where crystalloid solutions alone are insufficient to maintain adequate circulation.
• Hypoalbuminemia in critical illness: Severely ill patients in intensive care settings who develop dangerously low albumin levels contributing to fluid shifts and organ dysfunction.
• Liver cirrhosis with ascites: Patients undergoing large-volume paracentesis (drainage of ascitic fluid) benefit from albumin replacement to prevent circulatory dysfunction.
• Nephrotic syndrome: Severe cases with significant edema unresponsive to diuretic therapy may require albumin infusion to improve fluid distribution.
• Therapeutic plasma exchange: Albumin is commonly used as a replacement fluid during plasmapheresis procedures.
• Cardiopulmonary bypass surgery: As a priming solution for the bypass circuit and for post-operative volume management.
• Neonatal hyperbilirubinemia: In severe cases, albumin infusion may be used adjunctively during exchange transfusion to enhance bilirubin binding.

What Should You Know Before Receiving Albumin Baxalta?

Contraindications

The primary contraindication for Albumin Baxalta is a known allergy (hypersensitivity) to human albumin preparations or to any of the excipients contained in the formulation, including sodium chloride, sodium caprylate, sodium acetyltryptophan, and water for injection. Allergic reactions to albumin products are rare but can be severe when they occur. If you have previously experienced an allergic or anaphylactic reaction to any human albumin product, you must inform your healthcare team immediately, as the use of Albumin Baxalta would be contraindicated.

It is important to note that while albumin is derived from human plasma, cross-reactivity allergies between different manufacturers' albumin products are possible, as the manufacturing processes and excipient compositions may vary. Patients with a history of reactions to any plasma-derived product should be monitored with particular vigilance.

Warnings and Precautions

Before starting an infusion of Albumin Baxalta, your treating physician will carefully evaluate your medical condition and consider whether albumin is the most appropriate treatment option. Several pre-existing conditions require heightened caution and closer monitoring during albumin administration. You should inform your doctor if you have any of the following:

• Uncompensated heart failure: Albumin infusion increases circulating blood volume, which can worsen cardiac function in patients with decompensated heart failure by increasing the workload on an already struggling heart.
• Hypertension (high blood pressure): The volume-expanding effect of albumin may further elevate blood pressure, potentially leading to hypertensive complications including stroke or end-organ damage.
• Esophageal varices: Patients with dilated veins in the esophagus (commonly seen in liver cirrhosis) face an increased risk of variceal bleeding when intravascular volume is rapidly expanded.
• Pulmonary edema: Adding volume to the circulation can exacerbate fluid accumulation in the lungs, worsening respiratory function and potentially leading to respiratory failure.
• Hemorrhagic diathesis: Patients with a tendency toward spontaneous bleeding require careful volume management, as rapid volume expansion can dilute clotting factors and worsen coagulopathy.
• Severe anemia: Significant deficiency of red blood cells means that even with adequate volume expansion, oxygen delivery to tissues may remain compromised. Albumin does not carry oxygen and should not be used as a substitute for red blood cell transfusion.
• Renal anuria: Patients with absent urine production cannot excrete the additional fluid and sodium delivered with albumin, creating a risk of severe fluid overload.

For traceability purposes, it is strongly recommended that the product name and batch number of Albumin Baxalta be recorded each time it is administered to a patient. This practice enables the tracking of the specific product used, which is critically important in the unlikely event that a safety concern related to a particular batch is identified. Your healthcare facility will maintain these records as part of standard clinical practice.

Drug Interactions

No specific drug interactions with human albumin solutions are currently known. Albumin is a naturally occurring plasma protein, and its administration does not typically interfere with the pharmacological activity of other medications. However, because albumin is a major drug-binding protein in the blood, significant changes in serum albumin levels can theoretically affect the free (unbound) concentration of highly protein-bound drugs, potentially altering their pharmacological effect. Your treating physician will consider this when managing your overall medication regimen.

It is important to note that albumin solutions must not be mixed with other medications, whole blood, packed red blood cells, protein hydrolysates (such as parenteral nutrition solutions), or solutions containing alcohol, as such combinations can cause protein precipitation and render the product ineffective or potentially harmful.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, suspect that you may be pregnant, or are planning to become pregnant, inform your physician before receiving Albumin Baxalta. Human albumin is a naturally occurring component of blood, and its use during pregnancy and lactation should be determined by your doctor based on clinical necessity. The physician will weigh the potential benefits of treatment against any theoretical risks to determine whether Albumin Baxalta is appropriate for your specific clinical situation.

Clinical experience with the use of human albumin in pregnant women is extensive, as it has been used in obstetric emergencies and critical care settings for decades. There are no specific reproductive toxicity concerns associated with human albumin itself, as it is an endogenous protein. However, the decision to administer any blood-derived product during pregnancy requires careful medical judgment.

Sodium Content

How Does Albumin Baxalta Interact with Other Drugs?

Human albumin is an endogenous protein that circulates naturally in the blood, and clinical experience over many decades has not identified specific harmful interactions between albumin infusion products and other medications. Unlike many synthetic drugs, albumin does not undergo hepatic metabolism through cytochrome P450 enzymes or other drug-metabolizing pathways that commonly mediate drug-drug interactions.

However, several important considerations apply when albumin is administered alongside other treatments:

Compatibility Restrictions

Albumin solutions have strict compatibility requirements that must be observed to ensure patient safety and product efficacy:

Protein Binding Considerations

Albumin is the most abundant protein in blood plasma and serves as the primary binding protein for many drugs. When serum albumin levels change significantly—either through disease processes that reduce albumin or through therapeutic albumin infusion that increases it—the free (pharmacologically active) fraction of highly protein-bound drugs may be altered. This is particularly relevant for drugs with narrow therapeutic indices that are extensively bound to albumin, such as warfarin, phenytoin, and valproic acid. Your treating physician and clinical pharmacist will monitor drug levels and therapeutic effects accordingly.

Coagulation Factor Dilution

When large volumes of albumin are administered, there is a potential for dilution of circulating coagulation factors, platelets, and other blood components. This dilutional coagulopathy can increase bleeding risk, particularly in patients who are already at risk due to surgical procedures, trauma, or underlying coagulation disorders. Appropriate replacement of other blood components, including coagulation factors, electrolytes, and platelets, must be ensured when significant albumin volumes are given.

What Is the Correct Dosage of Albumin Baxalta?

Unlike many medications with fixed dosing schedules, the administration of Albumin Baxalta is entirely individualized. Your doctor will determine the appropriate dose, infusion rate, and duration of treatment based on your specific clinical needs. Throughout the infusion, your medical team will closely monitor your condition, including regular measurement of blood pressure, heart rate, central venous pressure (if applicable), respiratory status, and urine output. Blood samples will be taken to assess your albumin levels, electrolyte balance, hematocrit, and coagulation parameters.

Adults

Children

Elderly Patients

Elderly patients may have reduced cardiac reserve and impaired renal function, making them particularly susceptible to fluid overload during albumin infusion. No specific dose adjustment is defined, but the infusion rate should generally be slower and monitoring should be more frequent in older patients. The treating physician will carefully assess the patient's cardiovascular status before and throughout the infusion, adjusting the rate and total volume as needed to prevent circulatory overload.

Overdose

If hypervolemia develops, the standard clinical approach includes cessation of the albumin infusion, elevation of the head of the bed, administration of diuretics if appropriate, and supportive care to manage the excess intravascular volume. In severe cases, mechanical ventilation may be required if pulmonary edema develops. There is no specific antidote for albumin overdose; management is supportive and aimed at treating the hemodynamic consequences of volume overload.

What Are the Side Effects of Albumin Baxalta?

Like all medicines, Albumin Baxalta can cause side effects, although not everyone who receives it will experience them. Most patients tolerate albumin infusions well when they are administered at the appropriate rate under proper medical supervision. However, as with any blood-derived product, hypersensitivity reactions can occur and must be treated as a medical emergency.

If you experience any symptoms such as difficulty breathing, facial swelling, widespread rash, rapid drop in blood pressure, dizziness, or palpitations during or after an albumin infusion, alert your healthcare team immediately. The infusion will be stopped and appropriate emergency treatment will be provided.

When to Seek Immediate Medical Attention

Because Albumin Baxalta is administered in a hospital setting, your healthcare team will be monitoring you throughout the infusion. However, it is important that you communicate any unusual sensations or discomfort immediately. The following symptoms require urgent medical assessment:

• Sudden difficulty breathing or wheezing
• Swelling of the face, lips, tongue, or throat
• Severe skin rash, hives, or widespread itching
• Feeling faint, dizzy, or lightheaded
• Rapid or irregular heartbeat
• Chest pain or tightness
• Severe headache that develops during or after the infusion
• Significantly reduced or absent urine output

Reporting Side Effects

Reporting suspected side effects after a medicine has been authorized is important for the ongoing monitoring of its benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (for example, the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom).

How Should You Store Albumin Baxalta?

Proper storage of Albumin Baxalta is essential to maintain the quality and safety of the product. In hospital settings, the pharmacy department is responsible for ensuring correct storage conditions, but understanding these requirements helps ensure that the product is handled appropriately throughout the supply chain. The following storage guidelines apply:

• Temperature: Store at or below 25°C (77°F). The product should be kept at a consistent temperature within this range. Brief excursions above this temperature during transport may be acceptable, but prolonged exposure to elevated temperatures can compromise protein stability.
• Freezing: Albumin Baxalta must not be frozen under any circumstances. Freezing can cause irreversible denaturation of the albumin protein, rendering the product unsafe for use and potentially causing serious adverse reactions if administered.
• Light protection: Keep the vial in its outer carton at all times to protect the solution from light exposure, which can accelerate protein degradation over time.
• After opening: The contents should be used immediately after the vial is opened (punctured). Any unused solution remaining in the vial after the infusion should be discarded appropriately. The product does not contain preservatives, so there is a risk of microbial contamination if the opened vial is stored.
• Expiry date: Check the expiry date printed on the label and outer carton before use. The expiry date refers to the last day of the month indicated. Do not use the product after this date.
• Visual inspection: Before administration, visually inspect the solution. Do not use Albumin Baxalta if the solution appears cloudy, contains visible particles or sediment, or if the seal on the vial is broken. Such changes may indicate protein instability or contamination.

Keep all medicines out of the sight and reach of children. Although Albumin Baxalta is a hospital-administered product, standard pharmaceutical storage precautions apply within healthcare facilities.

What Does Albumin Baxalta Contain?

Active Ingredient

The active substance in Albumin Baxalta 50 g/l is human albumin. Each 100 ml of solution contains a total of 5 grams of protein, of which at least 95% is human albumin. The albumin is derived from human plasma collected from carefully screened voluntary blood donors and processed through validated fractionation and purification methods that include virus inactivation and removal steps.

Albumin is the most abundant protein in human plasma, normally present at concentrations of 35 to 50 g/l. It is a single-chain polypeptide consisting of 585 amino acid residues with a molecular weight of approximately 66,500 daltons. The protein is highly water-soluble and is responsible for approximately 80% of the colloid osmotic pressure of blood.

Inactive Ingredients (Excipients)

Packaging

Albumin Baxalta 50 g/l is supplied as a clear, slightly viscous solution that may appear nearly colorless, yellow, amber, or green in color. These color variations are normal and do not affect the quality or safety of the product. The solution is provided in sealed glass vials in two sizes: 250 ml (containing 12.5 g of human albumin) and 500 ml (containing 25 g of human albumin). Each vial is a single-use container—any unused solution must be discarded after the vial has been opened.

The total sodium ion content of the solution is 130 to 160 mmol/l, which is an important consideration for patients on sodium-restricted diets or those with conditions exacerbated by sodium intake.

What Should Healthcare Professionals Know About Administering Albumin Baxalta?

The following information is intended for healthcare professionals involved in the preparation and administration of Albumin Baxalta. Proper technique and adherence to these guidelines are essential for patient safety and product efficacy.

Preparation and Administration

• Route: Albumin Baxalta 50 g/l is administered directly by the intravenous route.
• Dilution: The product must not be diluted with water for injection, as this can cause hemolysis in the recipient. If dilution is required for specific clinical scenarios, only appropriate isotonic solutions should be used as directed by institutional protocols.
• Integrity check: Before use, verify that the seal on the vial is intact. Discard the product if the seal is broken or if the solution shows any signs of leakage.
• Visual inspection: The solution should be clear and slightly viscous, appearing nearly colorless, yellow, amber, or green. Do not use solutions that are cloudy or contain precipitate, as this may indicate protein instability or contamination.
• Infusion set: Use a sterile, pyrogen-free, single-use infusion set. Before inserting the infusion spike through the rubber stopper, disinfect the stopper with an appropriate antiseptic agent.
• Timing: The infusion should be started immediately after connecting the infusion set to the vial. Any unused solution must be discarded.
• Temperature: If large volumes are to be administered, the product should be warmed to room temperature or body temperature before infusion to improve patient comfort and reduce the risk of hypothermia.

Monitoring Requirements

Patients receiving albumin infusion require close monitoring of the following parameters:

• Blood pressure, heart rate, and respiratory rate at regular intervals
• Central venous pressure (CVP) where available, particularly in critically ill patients
• Urine output to assess renal perfusion
• Serum albumin levels, electrolytes (particularly sodium and potassium), hematocrit, and coagulation parameters
• Signs and symptoms of circulatory overload, including headache, dyspnea, jugular venous distension, or elevated blood pressure
• Signs of allergic or anaphylactic reactions, especially during the first 15 to 30 minutes of infusion

When concentrated albumin preparations are administered, adequate hydration of the patient must be ensured. The infusion rate should be adjusted based on individual clinical circumstances and the specific indication. During therapeutic plasma exchange, the infusion rate should be matched to the rate of plasma removal.

Appropriate replacement of other blood components, including coagulation factors, electrolytes, and platelets, must be maintained. For batch traceability purposes, the product name and batch number should be documented in the patient's medical record each time Albumin Baxalta is administered.